==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Browse result page of THPdb

The total number entries retrieved from this search are 14
IDThPPIDNamePeptide SequenceLengthFunctional ClassificationDiseaseBrandCompanyPhysical AppearanceRoute of AdministartionCategoryTarget
1403Th1065Digoxin Immune Fab (Ovine)Heavy Chain: EVQLQQS Full view438IIaCardiacDIGIBINDGalaxo Smith KlineSterile lyophilized powder of antigen binding fragments (Fab) derived from specific antidigoxin antibodies raised in sheep.Intravenous infusion after reconstitution with Sterile Water for InjectionAntidotes T-cell surface glycoprotein CD3 delta chain, T-cell surface glycoprotein CD3 epsilon chain, T-cell surface glycoprotein CD3 gamma chain, T-cell surface glycoprotein CD3 zeta chain, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c
1404Th1065Digoxin Immune Fab (Ovine)Heavy Chain: EVQLQQS Full view438IIaCardiacDigiFab Protherics IncSterile, purified, lyophilized preparation of digoxin-immune ovine Fab (monovalent) immunoglobulin fragments. Intravenous administration Antidotes T-cell surface glycoprotein CD3 delta chain, T-cell surface glycoprotein CD3 epsilon chain, T-cell surface glycoprotein CD3 gamma chain, T-cell surface glycoprotein CD3 zeta chain, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c
1454Th1084BecaplerminSLGSLTIAEPAMIAECKTRT Full view109IbCardiacREGRANEXOMJ Pharmaceuticals, Inc. San German, Puerto RicoGel: 0.01 %; clear, colorless to straw-colored gelExternal use onlyAngiogenesis Inducing Agents T-cell surface glycoprotein CD1a,Major histocompatibility complex class I-related gene protein,Integrin alpha-L,T-lymphocyte activation antigen CD86,Low affinity immunoglobulin gamma Fc region receptor II-b,T-cell surface glycoprotein CD4,Integrin beta-1,Integrin alpha-V,Integrin beta-3
1468Th1091BevacizumabDIQMTQSPSSLSASVGDRVT Full view214IIaCardiacAvastinGenentechSlightly opalescent, colorless to pale brown, sterile, pH 6.2 solution for intravenous infusionIntravenous infusionAngiogenesis Inhibitors Interleukin-2 receptor subunit alpha,Interleukin-2 receptor subunit beta,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c
1530Th1109NesiritideSPKMVQGSGCFGRKMDRISS Full view32IbCardiacNATRECORScios unit of Johnson & Johnson,White- to off-white lyophilized powderIntravenous injectionN.A. N.A.
1678Th1162AlirocumabNA Full view0IcMetabolic/CardiacPraluentSanofi Aventis U.S. LlcInjection, SolutionSubcutaneousN.A. Proprotein convertase subtilisin/kexin type 9
1679Th1162AlirocumabNA Full view0IcMetabolic/CardiacPraluentSanofi Aventis Canada IncSolutionSubcutaneousN.A. Proprotein convertase subtilisin/kexin type 10
1680Th1162AlirocumabNA Full view0IcMetabolic/CardiacPraluentSanofi Aventis Canada IncSolutionSubcutaneousN.A. Proprotein convertase subtilisin/kexin type 11
1681Th1162AlirocumabNA Full view0IcMetabolic/CardiacPraluentSanofi Aventis U.S. LlcInjection, SolutionSubcutaneousN.A. Proprotein convertase subtilisin/kexin type 14
1741Th1179EvolocumabNA Full view0IIaGenetic/Metabolic/CardiacNANAInjection, Solution; InjectionSubcutaneousLipid Modifying Agents, Plain; Cardiovascular System Proprotein convertase subtilisin/kexin type 9
1742Th1179EvolocumabNA Full view0IIaGenetic/Metabolic/CardiacRepathaAmgen IncInjection, SolutionSubcutaneousLipid Modifying Agents, Plain; Cardiovascular System Proprotein convertase subtilisin/kexin type 10
1743Th1179EvolocumabNA Full view0IIaGenetic/Metabolic/CardiacRepathaAmgen Canada IncSolutionSubcutaneousLipid Modifying Agents, Plain; Cardiovascular System Proprotein convertase subtilisin/kexin type 11
1744Th1179EvolocumabNA Full view0IIaGenetic/Metabolic/CardiacRepathaAmgen IncInjection, SolutionSubcutaneousLipid Modifying Agents, Plain; Cardiovascular System Proprotein convertase subtilisin/kexin type 12
1831Th1221C1 Esterase Inhibitor (Recombinant) NA Full view0IIaCardiac DisordersRuconestTjoapack Netherlands BvPowder and liquid for solutionIntravenousBlood and Blood Forming Organs Complement C1r subcomponent, Complement C1s subcomponent, Plasma kallikrein, Coagulation factor XII, Prothrombin, Coagulation factor XI, Tissue-type plasminogen activator